



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	Art Unit: 1647
Nielsen, et al.)	Examiner: Deberry, R.
Serial No: 09/674,733)	Washington, D.C.
Filed: May 2, 2001)	
For: METHODS FOR TREATMENT OF)	Docket No.: Nielsen=3B
DISEASES ASSOCIATED)	Confirmation No.: 3818
WITH INFLAMMATION UNDER)	
NON-ISCHEMIC CONDITIONS)	

DECLARATION OF ELSE TØNNESEN

U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

I hereby state and declare as follows:

1. I am a Professor and chief physician at the Department of Anaesthesiology and Critical Care at Aarhus University Hospital, Denmark.
2. I am a person skilled in the fields of anaesthesiology, critical care- and pulmonary medicine which with all respect appears from my CV (attached).
3. I am working with clinical and experimental studies to obtain an in depth understanding of the pathophysiological mechanisms responsible for organ damage in critically ill patients. We are currently conducting a series of studies using LPS induced inflammation in pigs to define the role of various cytokines (TNF-alpha, IL6 and IL10) for the inflammatory response seen in these conditions. Importantly, these studies have demonstrated that it is possible to interfere with the plasma concentrations of cytokines and protect against organ damage including the lungs.
4. I have read the Office Action dated December 14, 2004 and can assure you that experimentally inhalation of LPS is a widely recognized model for exacerbations of chronic obstructive pulmonary disease (COPD).
5. COPD is a chronic progressive disease associated with exacerbations. An exacerbation is defined as an acute worsening of a condition. Thus associated with COPD, an exacerbation can be defined clinically as a complex of respiratory symptoms (i.e. new onset or worsening of more

BEST AVAILABLE COPY

than one symptom such as cough, sputum, dyspnea or wheeze) lasting for at least 3 days, the exacerbation in COPD being characterized by eosinophilic and neutrophilic lung inflammation.

Experimentally, inhalation of lipopolysaccharide (LPS) induces an inflammatory response with eosinophil and neutrophil infiltrations that mimics the inflammatory response seen during an exacerbation in COPD.

For this reason, the model of acute lung inflammation induced by LPS inhalation is a used model to study exacerbations in COPD.

6. To emphasize the wide spread application of the LPS inhalation as a model for exacerbations in COPD, we have attached a list of references wherein the model is applied.
7. In addition to the general understanding that LPS inhalation is a recognized model for exacerbations in COPD, this approach is also valuable for proteomic studies identifying the pathogenic pathways involved in the progression of COPD.
8. Examples of practical applications of the model has been highlighted in several scientific publications (Brigham and Meyrick, Am Rev Respir Dis. 133:913-27, 1986; Wagner et al., Am J Respir Cell Mol Biol 20:769-776, 1999; Arsalane et al., Am J Respir Crit Care Med 161:1624-1630, 2000; Ridger et al., J Immunol 166:3484-90, 2001).
9. Conclusively, it is without doubt that exacerbations in COPD occur commonly and are characterized by an inflammatory pattern including the release of several cytokines and cell adhesion molecules enhancing the mainly bronchial neutrophilic inflammation. Importantly, LPS inhalation is a recognized model to examine the effect of exacerbations in COPD.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: June 13, 2005

By: Dr. Else Tønnesen



BEST AVAILABLE COPY

List of selected references:

1. Brigham KL, Meyrick B. Endotoxin and lung injury. *Am Rev Respir Dis.* 133:913-27, 1986.
2. Wagner JG, Driscoll KE, Roth RA. Inhibition of pulmonary neutrophil trafficking during endotoxemia is dependent on the stimulus for migration. *Am J Respir Cell Mol Biol* 20:769-776, 1999.
3. Arsalane K, Broeckert F, Knoop B, Wiedig M, Toubau G, Bernard A. Clara cell specific protein (CC16) expression after lung inflammation induced by intratracheal lipopolysaccharide administration. *Am J Respir Crit Care Med* 161:1624-1630, 2000.
4. Ridger VC, Wagner SE, Wallace WAH, Hellewell PG. Differential effects of CD18, CD29, and CD49 integrin subunit inhibition on neutrophil migration in pulmonary inflammation. *J Immunol* 166:3484-90, 2001.
5. Bozinovski S, Jones JE, Vlahos R, Hamilton JA, Anderson GP. Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. *J Biol Chem* 277(45):42808-14, 2002.
6. Timmer W, Leclerc V, Birraux G, Neuhauser M, Hatzelmann A, Bethke T, Wurst W. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. *J Clin Pharmacol* 42(3):297-303, 2002.
7. Spond J, Case N, Chapman RW, Crawley Y, Egan RW, Fine J, Hey JA, Kreutner W, Kung T, Wang P, Minnicozzi M. Inhibition of experimental acute pulmonary inflammation by pirfenidone. *Pulm Pharmacol Ther* 16(4):207-14, 2003.
8. Frankenberger M, Menzel M, Betz R, Kassner G, Weber N, Kohlhauf M, Haussinger K, Ziegler-Heitbrock L. Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers. *Clin Exp Immunol* 138(3):507-16, 2004.
9. Laan M, Bozinovski S, Anderson GP. Cigarette smoke inhibits lipopolysaccharide-induced production of inflammatory cytokines by suppressing the activation of activator protein-1 in bronchial epithelial cells. *J Immunol* 173(6):4164-70, 2004.
10. Juergens UR, Engelen T, Racke K, Stober M, Gillissen A, Vetter H. Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes. *Pulm Pharmacol Ther* 17(5):281-7, 2004.
11. Nevin BJ, Bradley KJ. Comparative effects of inhaled budesonide and the NO-donating budesonide derivative, NCX 1020, against leukocyte influx and airway hyperreactivity following lipopolysaccharide challenge. *Pulm Pharmacol Ther* 17(4):219-32, 2004.
12. Bozinovski S, Cross M, Vlahos R, Jones JE, Hsueh K, Tessier PA, Reynolds EC, Hume DA, Hamilton JA, Geczy CL, Anderson GP. S100A8 chemotactic protein is abundantly increased, but only a minor contributor to LPS-induced, steroid resistant neutrophilic lung inflammation in vivo. *J Proteome Res* 4(1):136-45, 2005.

13. Nita I, Hollander C, Westin U, Janciauskiene SM. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. *Respir Res* 1;6(1):12, 2005.
14. Ouagued M, Martin-Chouly CA, Brinchault G, Leportier-Corroy C, Depince A, Bertrand C, Lagente V, Belleguic C, Pruniaux MP. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients. *Pulm Pharmacol Ther* 18(1):49-54, 2005.

CURRICULUM VITAE

Personal data

Else Tønnesen, Professor, Consultant Anaesthesiologist, DMSc
Born August 28th 1948

Dept. of Anaesthesiology and Intensive Care
University Hospital of Aarhus
Noerrebrogade 44
DK-8000 Aarhus C

Tel. +45 8949 2869
Fax +45 8949 2880

e-mail: etonn@as.aaa.dk

Private address: Filosofgangen 1, DK-5000 Odense C
Tel. +45 6611 5258
e-mail: e.tonnesen@dadlnet.dk

- 1968 Advanced level in mathematics and physics
- 1975 Doctor of Medicine, MD, University of Aarhus
- 1984-87 Clinical assistant, University Hospital of Odense
- 1988 Authorised as Specialist in Anaesthesiology after education in Sweden
(Falköping and Malmö), Esbjerg Centralsygehus and University Hospital of
Odense
- 1992-95 Consultant and lecturer at Dept. of Anaesthesiology and Intensive Care,
University Hospital of Odense
- 1993-95 Vice Rector of the University of Southern Denmark
- 01.09.95- Professor and Consultant, Department of Anaesthesiology and Intensive
Care, Aarhus University Hospital
- 01.02.02- Vice Dean at the Faculty of Health Sciences, University of Aarhus

Research activities

DMSc in 1989 from University of Southern Denmark with the dissertation *"Immunological aspects of anaesthesia. With special reference to NK cells"*. Has published approximately 100 original papers and reviews in addition to case reports and other publications. Eight book chapters. Three chapters in textbooks editorial process. More than 150 speeches/poster presentations and approximately 35 guest lectures.

Selected references since 2002

1. Toft P, Dagnæs-Hansen F, Tønnesen E, Petersen MS. Influence of surgery and endotoxin-induced sepsis on natural killer cell activity, oxidative burst of granulocytes and antigen presentation capability of monocytes. *Acta Anaesthesiol Scand* 2002;46:405-410.
2. Toft P, Brix-Christensen V, Bæch J, Krog J, Jørgensen HS, Tønnesen E, Petersen TK, Dagnæs-Hansen F. Effect of hemodiafiltration and sepsis on chemotaxis of granulocytes and the release of IL-8 og IL-10. *Acta Anaesthesiol Scand* 2002;46:138-144.

3. Brix-Christensen V, Tønnesen E, Hjortdal VE, Flø C, Marqversen J, Frølund J, Ravn HB. Neutrophils and platelets accumulate in the heart, lungs and kidneys after cardiopulmonary bypass in neonatal pigs. *Crit Care Med* 2002;30:670-6.
4. Rasmussen M, Zhu W, Tønnesen J, Cadet P, Tønnesen E, Stefano GB. Effects of morphine on tumour growth. *Neuro Endocrinology Letters* 2002;23:193-98.
5. Glavind-Kristensen M, Brix-Christensen V, Tønnesen E, Ravn H, Forman A, Sørensen K, Hjortdal V. Pulmonary endothelial dysfunction after cardiopulmonary bypass in neonatal pigs. *Acta Anaesthesiol Scand* 2002; 46: 853-9.
6. Chew M, Brix-Christensen V, Brandslund I, Ravn HB, Hjortdal V, Hjortholm K, Hansen OK, Tønnesen E. Tissue injury and the inflammatory response to paediatric surgery with cardiopulmonary bypass. *Perfusion* 2002; 17; 327-33.
7. Krog J, Hokland M, Ahlburg P, Parner E, Tønnesen E. Lipid solubility and concentration dependent attenuation of *in vitro* natural killer cell cytotoxicity by local anaesthetics. *Acta Anaesthesiol Scand* 2002; 46: 876-81.
8. Toft P, Tønnesen E. Fast recovery of myoglobinuric acute renal failure treated with CVVHD. Case reports and Clinical Practise Review. 2003; 4:1
9. Toft P, Andersen SK, Tønnesen E. Det systemisk inflammatoriske respons ved akutte traumer. *Ugeskr Læger* 2003;167:669-71.
10. Brix-Christensen V, Vestergaard C, Chew M, Johnsen C, Andersen SK, Dreyer K, Hjortdal VE, Ravn HB, Tønnesen E. Plasma cytokines do not reflect expression of pro- and antiinflammatory cytokine mRNA at organ level after cardiopulmonary bypass in neonatal pigs. *Acta Anaesthesiol Scand*, 2003;47:525-31.
11. Krog J, Hokland M, Andersen SK, Tønnesen E. Phenotypic characterisation of porcine counterparts of human NK cell populations. *APMIS* 2003; 109:133-9.
12. Andersen SK, Gjedsted J, Christensen C, Tønnesen E. The roles of insulin and hyperglycemia in sepsis pathogenesis. *J Leukocyte Biology* 2003;75:413-21.
13. Tønnesen E. Xigris – activated protein C. *Ugeskr Laeger* 2004;166:2002-4.
14. Larsson A, Tønnesen E. The SAFE study. *Ugeskr Laeger* 2004
15. Mørcke AM, Wichmann Hansen G, Guldbrand Nielsen D, Tønnesen E, Eika B. Searching the core of emergency medicine. *Acta Anaesthesiol Scand* 2004;48:243-8.
16. Christensen C, Toft P, Jørgensen HS, Andersen SK, Tønnesen E. Hyperglycemia and mortality in critically ill patients. A prospective study. *Intensive Care Med*, 2004;30:1685-8.
17. Brix Christensen V, Rehling M, Flø C, Ravn H, Hjortdal V, Marqversen J, Andersen N Tønnesen E. Neutrophils and platelet dynamics at organ level after cardiopulmonary bypass. An *in vivo* study in neonatal pigs. *APMIS* 2004;112:133-40.
18. Brix Christensen V, Andersen SK, Dyhr T, Andersen R, Mengel A, Dyhr T, Andersen NT, Anders Larsson A, Schmitz O, Ørskov H, Tønnesen E. Acute hyperinsulinemia restrains endotoxin induced systemic inflammatory response – An experimental study in a porcine model. *Anesthesiology*, 2004;100: 861-70.
19. Kølsen Petersen JA, Nielsen JOD, Tønnesen E. The effect of hypertonic saline on postoperative cellular immune function. A randomised controlled clinical trial. *Anesthesiology* 2004; 100: 1108-18
20. Olsen P, Rasmussen M, Stefano GB, Tønnesen E. Morphine affects proliferation of tumour cells. *Ugeskr. Laeger* 2004;48:4347-50.
21. Cadet P, Rasmussen P, Zhu W, Tønnesen E, Mantione KL, Stefano GB. Endogenous morphine signaling and tumor growth. *Front Biosci* 2004;9:176-81.
22. Kølsen-Petersen JA, Dich Nielsen JO, Tønnesen E. Acid base and electrolyte changes after hypertonic saline (7.5%) infusion: a randomized controlled clinical trial *Scand J Clin Invest* 2005;65:13-22.
23. Nielsen JS, Larsson A, Brix-Christensen V, Nyengaard JR, Ledet T, Tønnesen E. Endotoxemic induced lymphocyte apoptosis is augmented by a hyperinsulinemic euglycemic clamp. *Anesthesiology*, 2005:102;768-.
24. Olsen P, Rasmussen M, Zhu W, Tønnesen E, Stefano GB. Human gliomas contain morphine. *Med Sci Monit* 2005;11:18-21